Research programme: adoptive T-cell therapy - Tactiva Therapeutics

Drug Profile

Research programme: adoptive T-cell therapy - Tactiva Therapeutics

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roswell Park Cancer Institute; Tactiva Therapeutics
  • Developer Tactiva Therapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 May 2017 Tactiva Therapeutics plans phase I/IIa trial for Solid tumours
  • 05 Apr 2017 Pharmacodynamics data from Preclinical studies in Solid tumours presented at the Annual Meeting of the American Association of Cancer Research (AACR-2017)
  • 01 Jan 2017 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top